Phase 1/2, Randomized, Observer-Blind, Parallel, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults ≥18 Years of Age

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 13 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRNA 1018 (Primary)
Indications Influenza virus infections
Focus Adverse reactions
Sponsors Moderna Therapeutics

Most Recent Events

09 Aug 2024 Status changed from active, no longer recruiting to completed.
02 Jul 2024 According to a Moderna Therapeutics media release, the company expects results from this trial in 2024 and will inform Phase 3 development plans.
30 Jan 2024 Planned End Date changed from 22 May 2024 to 26 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight